Rhythm Pharmaceuticals (RYTM) said Friday the US Food and Drug Administration has approved an expanded indication for IMCIVREE to include children as young as 2 years old.
The drug is indicated to lower excess body weight and keep weight reduction long-term in patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome or genetically confirmed pro-opiomelanocortin.
Rhythm shares were up more than 2% in recent trading.
Price: 56.65, Change: +1.17, Percent Change: +2.11
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments